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Mutations in leucine-rich repeat kinase 2 (LRRK2)
are a common cause of familial and sporadic
Parkinson’s disease (PD). Elevated LRRK2 kinase
activity and neurodegeneration are linked, but the
phosphosubstrate that connects LRRK2 kinase
activity to neurodegeneration is not known. Here,
we show that ribosomal protein s15 is a key patho-
genic LRRK2 substrate in Drosophila and human
neuron PD models. Phosphodeficient s15 carrying
a threonine 136 to alanine substitution rescues
dopamine neuron degeneration and age-related
locomotor deficits in G2019S LRRK2 transgenic
Drosophila and substantially reduces G2019S
LRRK2-mediated neurite loss and cell death in
human dopamine and cortical neurons. Remark-
ably, pathogenic LRRK2 stimulates both cap-
dependent and cap-independent mRNA translation
and induces a bulk increase in protein synthesis
in Drosophila, which can be prevented by phospho-
deficient T136A s15. These results reveal a novel
mechanism of PD pathogenesis linked to elevated
LRRK2 kinase activity and aberrant protein synthe-
sis in vivo.472 Cell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc.INTRODUCTION
Following the identification of pathogenic leucine-rich repeat
kinase 2 (LRRK2) mutations that lead to Parkinson’s disease
(PD) in 2004 (Paisa´n-Ruı´z et al., 2004; Zimprich et al., 2004),
LRRK2 mutations are now known to be the most common
genetic cause of PD, accounting for up to 40% of familial cases
in certain populations (Martin et al., 2011). LRRK2 mutations
result in clinical and pathological features that closely resemble
the more common sporadic PD, suggesting that understanding
LRRK2-linked disease mechanisms may be a gateway to under-
standing sporadic PD. Multiple lines of evidence indicate that
LRRK2 kinase activity is key to PD development, particularly
the findings that (1) the common G2019S mutation bestows
increased kinase activity toward generic kinase substrates
(Anand et al., 2009; Covy and Giasson, 2009; Greggio
et al., 2006; Luzo´n-Toro et al., 2007; Smith et al., 2006; West
et al., 2007), and (2) LRRK2 toxicity is kinase-dependent
(Deng et al., 2011; Greggio et al., 2006; Lee et al., 2010;MacLeod
et al., 2006; Smith et al., 2006). To understand the link between
LRRK2 kinase activity and PD development, it is imperative
to identify authentic LRRK2 substrates that are linked to neuro-
degeneration in PD (Tsika and Moore, 2012).
LRRK2 is a large multidomain protein with several protein-
protein interaction domains and a catalytic core containing
GTPase, C-terminal of ROC (COR), and kinase domains where
mostPD-linkedmutations are found. It is likely that its physiologic
and pathophysiologic functions are mediated through protein-
protein interactions and/or phosphorylation of LRRK2 substrates
(Cookson, 2010). A number of candidate LRRK2 substrates have
been identified. LRRK2 kinase activity is part of an endophilin A
phosphorylation cycle that promotes efficient synaptic vesicle
endocytosis at the neuromuscular junction (Matta et al., 2012).
Phosphorylation of ezrin/radixin/moesin by LRRK2 promotes
the rearrangement of the actin cytoskeleton in neuronal morpho-
genesis (Parisiadou et al., 2009). LRRK2 phosphorylation of
eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP)
has been suggested to couple increased LRRK2 kinase activity
to aberrant translation of a small number of mRNAs through
4E-BP-dependent perturbation of microRNA activity (Gehrke
et al., 2010; Imai et al., 2008). However, while this study raises
the possibility that LRRK2 may affect translation at some level,
a mechanistic link involving phospho-4E-BP is lacking as there
was no direct demonstration that LRRK2 phosphorylation of
4E-BP mediates altered translation of these mRNAs. Moreover,
recent studies suggest that 4E-BPmaynotbean important in vivo
LRRK2 substrate (Kumar et al., 2010; Trancikova et al., 2012)
raising additional doubt on the role of 4E-BPasakinase substrate
important in LRRK2 toxicity. Thus, how elevated LRRK2 kinase
activity is coupled to aberrant mRNA translation and neurode-
generation in PD remains to be clarified.
In order to understand the connection between LRRK2 kinase
activity and neurotoxicity, candidate LRRK2 substrates were
identified through LRRK2 tandem affinity purification and
in vitro kinase screening of LRRK2-interacting phosphoproteins.
We find that ribosomal proteins are major LRRK2 interactors and
LRRK2 kinase targets and that LRRK2 is markedly enriched in
the ribosomal subcellular fraction. Blocking phosphorylation of
the small ribosomal subunit protein s15 rescues LRRK2 neuro-
toxicity in human dopamine neurons and Drosophila PDmodels.
We demonstrate that pathogenic LRRK2 induces an increase in
bulk protein synthesis in flies, which is blocked by phosphodefi-
cient s15. Moreover, the global protein synthesis inhibitor
anisomycin rescues the locomotor deficits and dopamine
neuron loss in aged G2019S LRRK2 transgenic Drosophila.
Our findings identify s15 as a key pathogenic LRRK2 substrate
that links elevated LRRK2 kinase activity to Parkinson’s disease
pathogenesis via altered translation.
RESULTS
Identifying Candidate LRRK2 Kinase Substrates
LRRK2-interacting phosphoproteins were identified by tandem
affinity purification (TAP) of LRRK2 from HEK293 cells. A
LRRK2 TAP tag was generated by fusing a streptavidin binding
peptide and a calmodulin binding peptide to the C terminus of
LRRK2. TAP-tagged LRRK2 complex retains kinase activity (Fig-
ures 1A–1C). LRRK2-interacting phosphoproteins were enriched
by immobilizedmetal affinity chromatography (IMAC) (Figure 1D)
and then separated via SDS-PAGE. The gel was divided into
multiple even-sized pieces and protein bands were identified
by mass spectrometry. To control for nonspecific binding, pro-
teins identified by TAP of two unrelated proteins, Botch and
GADD45b were subtracted from the mass spectrometry data
set for LRRK2, leaving 161 interacting proteins (Table S1 avail-able online). A Cytoscape network analysis reveals that themajor
LRRK2 interacting proteins identified by this approach are
functionally categorized into four major groups; structural
constituents of the ribosome, proteins involved in transporter
activity, nucleotide binding, and cation binding (Figure S1A). To
determine which of these interacting proteins are direct LRRK2
substrates, GST-fusion proteins were generated by Gateway
cloning and screened via an in vitro LRRK2 kinase assay to
assess phosphorylation in the presence of wild-type LRRK2,
kinase-dead LRRK2 (D1994A), and two disease-causing
variants with kinase domain mutations, G2019S LRRK2 and
I2020T LRRK2 (Figure S1B). Approximately 60% of all GST-
fusion proteins were amenable to purification (Table S1). Eleven
proteins are phosphorylated by wild-type, G2019S and I2020T
LRRK2, but not by kinase-dead D1994A LRRK2. Ten candidate
substrates are ribosomal proteins and the other protein is lactate
dehydrogenase B (LDHB) (Figures 1E and S1C). Consistent with
our finding that LRRK2 interacts with and phosphorylates
ribosomal proteins, endogenous LRRK2 is highly enriched in
the ribosomal subcellular fraction suggesting that LRRK2 might
play an important role in ribosomal function and mRNA transla-
tion (Figure 1F). Similar levels of enrichment are observed for
overexpressed wild-type, D1994A, and G2019S LRRK2 (data
not shown), suggesting that the physical association of LRRK2
with ribosomes is not kinase-dependent. To further determine
the scope of LRRK2 actions at the ribosome, all known ribo-
somal proteins belonging to the human 40S and 60S subunits
amenable to purification were subjected to in vitro LRRK2 kinase
assays (Table S2). A total of 19 ribosomal proteins are phosphor-
ylated by LRRK2 (Table S2). Three substrates belonging to the
40S ribosomal subunit, s11, s15, and s27, exhibit significantly
increased phosphorylation by the pathogenic mutants G2019S
and I2020T LRRK2 (Figure 1E). We reasoned that substrates
exhibiting elevated phosphorylation with pathogenic LRRK2 var-
iants might be involved in LRRK2 toxicity. To identify phosphor-
ylation sites on these three ribosomal proteins, tandem mass
spectrometry analysis was performed following LRRK2 phos-
phorylation in vitro (Figures S2A and S2B). LRRK2 phosphory-
lates threonine 136 of s15 and threonines 28, 46, and 54 of s11
(Figures S2A and S2B). We are unable to detect phosphorylation
of s27 by LRRK2 via mass spectrometry (data not shown).
s15 Is a Pathogenic LRRK2 Substrate in Human
Dopamine Neurons
A substitution of threonine 136 to alanine in s15 significantly
reduces wild-type, G2019S, and I2020T LRRK2 phosphorylation
of s15 (Figure 2A). A triple mutation of threonines 28, 46, and 54
to alanines in s11 eliminates phosphorylation of s11 bywild-type,
G2019S, and I2020T LRRK2 (Figure S2C). To ascertain whether
s15 or s11 phosphorylation are required for LRRK2 toxicity, the
effects of T136A s15 and triple mutant (T28A, T46A, T54A) s11
were examined. G2019S LRRK2 has been repeatedly shown to
cause kinase-dependent neuronal toxicity characterized by neu-
rite loss and cell death in rodent and human neurons (Greggio
et al., 2006; Lee et al., 2010; Ramsden et al., 2011; Smith
et al., 2006; West et al., 2007). Phosphodeficient T136A s15 is
markedly protective against G2019S LRRK2 toxicity (neurite
loss and cell death) whereas triple mutant s11 failed to influenceCell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc. 473
Figure 1. Identification of Candidate LRRK2 Substrates
(A) Cartoon of LRRK2 TAP construct with C-terminal streptavidin binding peptide (SBP) and calmodulin binding peptide (CBP) tags and scheme for identifying
LRRK2-interacting phosphoproteins.
(B) LRRK2 TAP copurified proteins visualized by coomassie and silver stained polyacrylamide gels. Control is empty vector.
(C) Phosphorimaging of LRRK2 complex purified by TAP demonstrating that it was kinase active.
(D) IMAC enrichment of phosphoproteins from TAP eluate. FT, flow-through; Elu, eluate.
(E) LRRK2 kinase substrates exhibiting significantly increased phosphorylation (g-32P-ATP incorporation) by G2019S and I2020T LRRK2 compared toWT LRRK2
(individual one-way ANOVA for effect of LRRK2 variant, p < 0.0001, Bonferroni posttest, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 3–7). Coomassie brilliant
blue-stained gels are shown.
(F) Endogenous LRRK2 levels in HEK293 cell whole lysates, nuclear (Nuc), mitochondrial (Mito), or ribosomal (Ribo) subcellular fractions. Endogenous LRRK2 is
enriched in ribosomal fractions (ANOVA followed by Bonferroni posttest, ***p < 0.001, n = 3). Data are mean ± SEM.
See also Figure S1 and Tables S1 and S2.LRRK2 toxicity in rat cortical neurons (Figures 2B and S2C).
Overexpression of s15 is modestly toxic to rat cortical neurons
but overexpression of T136A s15, s11 or triple mutant s11 are
not (Figures 2B and S2C). T136A s15 is additionally protective
against the kinase domain mutant I2020T LRRK2, but not the
pathogenic ROC domain mutant R1441C LRRK2 (Figure S2D).
Coexpression of wild-type s15 did not substantially influence
toxicity for any of the LRRK2 variants tested. To further explore
the role of s15 phosphorylation in LRRK2 toxicity, the effect of
phosphomimetic T136D s15 was examined. T136D s15 alone
is sufficient to induce neuronal toxicity and when expressed
together with G2019S LRRK2, did not exacerbate LRRK2474 Cell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc.toxicity (Figure 2C) consistent with G2019S LRRK2 toxicity being
mediated via s15 phosphorylation. To extend our investigation
and probe the role of s15 in human neurotoxicity caused
by G2019S LRRK2, human midbrain dopamine neurons and
cortical neurons were derived from human embryonic stem cells
and characterized (Figures S3A and S3B). G2019S LRRK2
causes neurotoxicity in human midbrain dopamine neurons (Fig-
ure 3A) and in human cortical neurons (Figure 3B), where it
results in significantly elevated endogenous phospho-T136 s15
levels (Figure S3C), observed using a validated phosphospecific
antibody to phospho-T136 (Figures S3D–S3F). LRRK2 toxicity in
both human dopamine and cortical neurons is significantly
Figure 2. Phosphodeficient s15 Protects against LRRK2 Toxicity
(A) LRRK2 in vitro kinase assay. T136A (TA) s15 reduces phosphorylation bywild-type (WT), D1994A (DA), G2019S (GS), and I2020T (IT) LRRK2 (two-way ANOVA,
p < 0.0001 for effect of T136Amutation, n = 3), and prevents the increase in s15 phosphorylation via G2019S and I2020T LRRK2 (Bonferroni posttest, ***p < 0.001;
ns, not significant).
(B) T136A (TA) s15 blocks G2019S LRRK2 toxicity (neurite shortening and cell death) in rat cortical neurons (individual ANOVA, Bonferroni posttests, *p < 0.05,
***p < 0.001, ****p < 0.0001, n = 5). Arrows indicate neurons lacking neurites, a subset of which are TUNEL-positive (see inset magnifications) as indicated. The
vast majority of GFP-positive neurons (90%) colabeled for LRRK2 and s15 when cotransfected (data not shown).
(C) Phosphomimetic T136D (TD) s15 mimics G2019S LRRK2 toxicity (individual ANOVA, Bonferroni posttest, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3). Scale bars
represent 25 mM. Data are mean ± SEM.
See also Figure S2.attenuated by T136A s15 but not wild-type s15. Phosphomi-
metic T136D s15 is toxic to both types of neurons (Figures 3A
and 3B). Partial knockdown (50%) of s15 in human cortical
neurons partially rescues neuronal toxicity caused by G2019S
LRRK2, similar to that observed for T136A s15 (Figure S3G),
while expression of G2019S LRRK2 is not affected (Figure S3G).
Finally, increasing wild-type LRRK2 overexpression leads to a
modest increase in s15 phosphorylation and neuronal toxicity,
but not to the extent observed via G2019S LRRK2 (Figures
S3H and S3I). Taken together, these data reveal that s15 is a
pathogenic LRRK2 substrate for LRRK2 mutations within the
kinase domain of LRRK2 and that LRRK2 and s15 act in the
same cell death pathway.s15 Is an Authentic LRRK2 Substrate In Vivo
Because phosphorylation of s15 by LRRK2 was found to be
required for LRRK2 neurotoxicity, the interaction and phosphor-
ylation of s15 by LRRK2 was further investigated. Recombinant
s15 is phosphorylated by wild-type LRRK2 with a Km of 1.5 mM
and by G2019S LRRK2 with a Km of 0.7 mM, suggesting a
stronger substrate affinity between s15 and G2019S LRRK2
compared to that with wild-type LRRK2 (Figure 4A). G2019S
and I2020T LRRK2 both increase phospho-s15 levels in cells
whereas overexpression of the ROC domain mutants R1441C
or R1441G do not (Figure 4B). These phosphorylation results
are consistent with the ability of the T136A s15 mutant to rescue
G2019S and I2020T LRRK2 neurotoxicity but not R1441CCell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc. 475
Figure 3. Phosphodeficient s15 Protects
against G2019S LRRK2 Toxicity in Human
Dopamine and Cortical Neurons
G2019S LRRK2 toxicity (neurite shortening and
cell death) in human midbrain dopamine neurons
(A) (white arrows) and human cortical neurons (B)
is phenocopied by phospho-mimetic T136D (TD)
s15 and rescued by phosphomutant T136A
(TA) s15 but not wild-type s15. Individual
ANOVA, Bonferroni posttest, *p < 0.05, **p < 0.01,
***p < 0.001, n = 4). Scale bars represent 25 mM.
Data are mean ± SEM.
See also Figure S3.neurotoxicity (see Figures 2 and S2). LRRK2-IN-1 and CZC-
25146, two potent LRRK2 kinase inhibitors with nonoverlapping
off-target kinase inhibition (Deng et al., 2011; Ramsden et al.,
2011) block G2019S LRRK2 phosphorylation of s15 both in
kinase assays in vitro and in cell culture (Figures 4C, S4A, and
S4B). The G2019S/A2016T LRRK2 variant is resistant to
LRRK2-IN-1 kinase inhibition, and phosphorylation of s15 by
this LRRK2 variant is unaffected by LRRK2-IN-1 treatment (Fig-
ure 4C), further supporting that reduced s15 phosphorylation is
caused specifically by LRRK2 kinase inhibition. Endogenous
LRRK2 and s15 both exhibit punctate immunostaining with
partial perinuclear colocalization in human cortical neurons (Fig-
ures 4D and S4C), which is also found for overexpressed
G2019S LRRK2 and s15 (Figure S4C). Endogenous s15 and
LRRK2 coimmunoprecipitate and s15 interacts with the WD40
protein interaction domain of LRRK2 (Figure S4D). Postmortem
cortex from human G2019S carriers exhibit increased s15 phos-
phorylation in ribosomal fractions (Figure 4E). LRRK2 expression
was not significantly different in G2019S carrier ribosomal frac-
tions or whole lysates compared to control patient brain samples
(Figures 4E and S4F). Finally, ribosomal fractions from dLRRK
(Drosophila LRRK2 homolog) null fly heads exhibit significantly
reduced s15 phosphorylation (Figure 5A) whereas phospho-476 Cell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc.s15 is significantly increased in head
ribosomal fractions from G2019S trans-
genic flies but not kinase-dead G2019S/
D1994A LRRK2 flies (Figure 5B). As in hu-
man cells, endogenous s15 and dLRRK
exhibit partial colocalization around the
nucleus of Drosophila S2 cells (Fig-
ure S4G). These data collectively demon-
strate that s15 is an authentic and direct




To determine whether s15 phos-
phorylation underlies LRRK2-dependent
neurodegeneration and PD-related phe-
notypes in vivo, we used the robust and
efficient Drosophila LRRK2 transgenic
model in which flies expressing human
G2019S LRRK2 rapidly exhibit aging-related dopaminergic neurodegeneration and locomotor deficits
linked to increased LRRK2 kinase activity (Liu et al., 2008). Dopa-
mine neuron degeneration and locomotor dysfunction observed
in aged G2019S LRRK2 transgenic Drosophila are completely
rescued by coexpression of T136A s15 whereas wild-type s15
is not protective (Figures 5C, 5D, and S5A). Neither s15 nor
T136A s15 coexpression affects G2019S LRRK2 levels (Fig-
ure S5B). There were no effects of LRRK2, s15, or T136A s15
overexpression observed in young flies in these assays, consis-
tent with previous reports for LRRK2 transgenic flies at this age
(Liu et al., 2008) (Figures S5C and S5D). Also, neither s15 nor
T136A s15 expression alone significantly affects negative
geotaxis or dopamine neuron survival in aged flies, although
there was a slight reduction in climbing ability with s15 overex-
pression (Figures S5E and S5F). s15 is an integral ribosomal pro-
tein and knocking-down s15 by RNAi is lethal in Drosophila, via
whole-body or targeted neuronal expression (data not shown).
LRRK2 Stimulates Cap-Dependent and
Cap-Independent Translation
The role of s15 in LRRK2 toxicity raises the possibility that path-
ogenic LRRK2 might modulate the activity of ribosomes to
impact protein synthesis in an s15-dependent manner. Although
Figure 4. Phosphorylation of s15 by Pathogenic LRRK2 Variants and Block by LRRK2-IN-1
(A) Kinetics of LRRK2 or G2019S LRRK2 initial enzyme velocity at various s15 concentrations for derivation of the Michaelis-Menten constant, Km. Data are
mean ± SEM, n = 3. Silver stained gels are shown.
(B) Phospho-s15 levels following cotransfection of HEK293 cells with V5 s15 and LRRK2. Densitometry revealed a significant effect of G2019S and I2020T LRRK2
variants on phospho-s15 levels (ANOVA followed by Bonferroni posttest, *p < 0.05, n = 5).
(C) LRRK2-IN-1 blocked V5 s15 phosphorylation by G2019S LRRK2 but not a drug-resistant variant, G2019S/A2016T LRRK2 in cotransfected HEK293 cells
(ANOVA, Bonferroni posttest, *p < 0.05, **p < 0.01, n = 3).
(D) Endogenous LRRK2 and s15 in human cortical neurons exhibit punctate immunostaining, predominantly in the perinuclear region where they colocalize. Scale
bars represent 10 mM.
(E) Phospho-s15 is increased in ribosomal fractions from G2019S LRRK2 human postmortem brains (Student’s t test, **p < 0.01). Whole lysates were run
separately (see Figure S4) due to gel space constraints. Data are mean ± SEM.
See also Figure S4.little is known about the role of s15 in translation, it is located on
the surface of the 40S ribosomal subunit and its C-terminal tail
(where T136 lies) is highly conserved among eukaryotes and
may extend into the ribosomal decoding site during mRNAtranslation (Khairulina et al., 2010; Pisarev et al., 2006). mRNA
translation can occur by both cap-dependent and cap-indepen-
dent mechanisms of ribosome binding. To simultaneously probe
the effects of LRRK2 on cap-dependent and cap-independentCell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc. 477
Figure 5. Rescue of Dopamine Neuron Degeneration and Locomotor Dysfunction in Aged G2019S LRRK2Drosophila by Phosphomutant s15
(A) Phospho-s15 is reduced in dLRRKe03680 (dLRRK null) homozygotes compared to isogenic w1118 controls (Student’s t test, p < 0.001, n = 4 groups of 100 fly
heads/genotype). L, whole lysates; R, ribosomal fractions.
(B) G2019S LRRK2 transgenic flies (Ddc-Gal4; UAS-G2019S-LRRK2) exhibit increased phospho-s15 (ANOVA, Bonferroni posttest, **p < 0.01; ***p < 0.001; ns,
not significant, n = 4 groups of 100 fly heads/genotype). L, whole lysates; R, ribosomal fractions. LRRK2 exhibits an additional high molecular weight band (likely
SDS-insoluble LRRK2).
(C) Aged flies expressing G2019S LRRK2 exhibit a significant locomotor deficit in negative geotaxis assays, which is rescued by T136A (TA) s15 expression
(ANOVA followed by Bonferroni posttest, *p < 0.05, **p < 0.01, n = 30–40 flies). Genotypes are Ddc-Gal4/+; +/+ (Control), UAS-s15/+; +/+ (s15), UAS-T136A s15/
+; +/+ (TA s15),Ddc-Gal4/+; UAS-LRRK2/+ (LRRK2),Ddc-Gal4/+; UAS-G2019S-LRRK2/+ (G2019S),Ddc-Gal4/UAS-s15; UAS-G2019S-LRRK2/+ (GS/s15), and
Ddc-Gal4/UAS-T136A s15; UAS-G2019S-LRRK2/+ (GS/TA s15).
(D) Dopamine neuron loss in aged G2019S LRRK2 flies is rescued by T136A s15 coexpression. Confocal projection images through the posterior fly brain show
five major dopamine neuron clusters (PPM1, PPM2, PPM3, PPL1, PPL2). Scale bars represent 60 mM. For quantitation, individual ANOVA followed by Bonferroni
posttest, *p < 0.05, **p < 0.01 ***p < 0.001, n = 10 fly brains per genotype. Genotypes are as in (C). Data are mean ± SEM.
See also Figure S5.translation, a bicistronic reporter composed of a FLAG readout
to monitor cap-dependent translation followed by an IRES site
with a c-Myc readout to monitor cap-independent translation
from the same transcript was utilized (Figure 6A). G2019S
LRRK2 dose-dependently increases both cap-dependent and
cap-independent reporter translation in a kinase-dependent
manner (Figure 6B), while reporter mRNA levels are not signifi-
cantly affected by LRRK2 expression (Figure S6A). Wild-type
s15 stimulates both cap-dependent and cap-independent
reporter translation in a dose-dependent manner (Figure 6C).478 Cell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc.Importantly, these effects are augmented by the phosphomi-
metic T136D mutation and subtly decreased by T136A s15,
without significant changes in reporter transcript levels (Figures
6C and S6A). To determine whether s15 phosphorylation medi-
ates the effects of LRRK2 on translation, cap-dependent and
cap-independent reporter translation induced by G2019S
LRRK2 was monitored in the presence of wild-type s15 or
T136A s15. Wild-type s15 modestly enhances the stimulation
of translation by G2019S LRRK2, whereas T136A s15 blocked
stimulation of both cap-dependent and cap-independent
translation by G2019S LRRK2 (Figure 6D). Reporter mRNA levels
are not significantly different between the groups (Figure 6D).
Partial knockdown of s15 similarly attenuates cap-dependent
and cap-independent reporter translation (Figure S6B) further
supporting the link between s15 and LRRK2 effects on transla-
tion. LRRK2 was previously reported to phosphorylate human
4E-BP1 and it was suggested that phospho-4E-BP1 affects
the expression of certain genes by repressing miRNA activity
(Gehrke et al., 2010). As expected, knockdown of DICER led to
reduced miRNA levels (data not shown) but failed to stimulate
bicistronic reporter expression (Figure S6C) suggesting that
G2019S LRRK2 does not promote reporter translation by impair-
ing the miRNA pathway. Similarly, overexpressing hAgo2, which
was proposed to be functionally impeded by phospho-4E-BP
binding, did not attenuate cap-dependent or cap-independent
reporter expression (Figure S6D). Because phosphorylation of
4E-BP blocks its ability to bind to and repress eIF4E, it is possible
that elevated levels of eIF4E could stimulate translation upon an
increase in phospho-4E-BP (Imai et al., 2008). However, while
4E-BP overexpression was previously reported to rescue loss
of dopamine neurons observed in flies expressing pathogenic
dLRRK variants (Imai et al., 2008), it did not reduce G2019S
LRRK2-mediated reporter expression in cells (Figure S6D).
Moreover, we did not detect an increase in phospho-4E-BP1
levels following G2019S LRRK2 expression in cells (Figure S6E)
or G2019S LRRK2 transgenic fly heads (Figure S6F), consistent
with other subsequent studies (Kumar et al., 2010; Trancikova
et al., 2012) that failed to find an increase in 4E-BP1 phosphory-
lation inmammalian cells expressing pathogenic LRRK2 variants
or LRRK2 transgenic mouse brain. Additionally, an increase in
4E-BP phosphorylation would not account for an increase
in cap-independent translation because neither eIF4E nor
4E-BP1 are known to be involved in this mode of translation.
Finally, partial loss of eIF4E expression did not block neurode-
generative phenotypes (age-related loss of dopamine neurons
and locomotor deficits) observed in aged G2019S transgenic
flies (Figures S6G–S6I). Collectively, these results suggest that
miRNA pathway impairment or elevated free eIF4E levels via
4E-BP1 phosphorylation does not play a major role in LRRK2-
induced translation.
Reporter expression in human ES cell-derived cortical
neurons is stimulated in G2019S LRRK2-expressing neurons
and this is blocked by T136A s15 coexpression (Figure 6E).
If the stimulatory effect of G2019S LRRK2 on translation
underlies its neuronal toxicity, then it might be expected that
reporter-positive neurons would exhibit disproportionately high
levels of toxicity. Indices of translation-linked neuronal injury
and translation-linked cell death in reporter-positive neurons
indicate that cell injury and death are coupled to increases in
translation (Figure 6E). G2019S LRRK2 stimulates reporter trans-
lation and increases both toxicity indices by 3-fold compared
to kinase-dead G2019S/D1994A LRRK2 in human cortical neu-
rons (Figure 6E). This effect is blocked by T136A s15 coexpres-
sion. Comparison of reporter-positive neurons with neighboring
reporter-negative neurons reveals 5-fold higher levels of neurite
toxicity in reporter-positive neurons and a similar difference in
levels of cell death under all conditions, further suggesting a
link between translation stimulation and LRRK2 toxicity (Fig-ure S6J). Taken together, these results suggest that phos-
phorylation of s15 on T136 by LRRK2 mediates enhanced
cap-dependent and cap-independent reporter translation and
that a stimulatory effect of LRRK2 on mRNA translation contrib-
utes to LRRK2 toxicity.
G2019SLRRK2 IncreasesBulk Translation inDrosophila
From our in vitro reporter assays, we hypothesized that patho-
genic LRRK2may cause a bulk shift in translation that, as shown
in other neurodevelopmental and neurodegenerative diseases,
can impair neuronal function. Consistent with our in vitro obser-
vations, 35S-methionine/cysteine pulse labeling of newly synthe-
sized protein was significantly increased in G2019S LRRK2
transgenic Drosophila heads (Figure 7A), suggesting an increase
in protein synthesis rates by LRRK2. In accordancewith its ability
to block LRRK2 toxicity, T136A s15 coexpression abolishes this
increase (Figure 7A). SDS-PAGE analysis of lysates indicates a
bulk increase in many proteins across a large range of molecular
weights by G2019S LRRK2 (Figure 7B). Assessment of house-
keeping gene mRNAs undergoing translation in monosome
and polysome fractions from fly heads reveals that G2019S
LRRK2 expression leads to an enrichment of mRNAs in heavy
polysome fractions, an effect which is attenuated by T136A
s15 (Figure 7C). This increase in density of ribosomes associated
with mRNA indicates that LRRK2 stimulates mRNA translation
and that an increased rate of protein synthesis underlies the
augmented protein levels observed via 35S-methionine/cysteine
labeling. Increased ribosomal density typically indicates an
increase in translation initiation, but could theoretically signal a
slower rate of ribosomal elongation or release upon termination.
Reduced elongation/termination rates are not consistent with an
increase in protein production, however, andG2019S LRRK2 did
not affect rates of ribosomal runoff following treatment of
cells with harringtonine, a drug that prevents translocation of ri-
bosomes engaged in initiation but not elongation (Figures S7A–
S7D). Hence, these data are consistent with an effect of
LRRK2 on initiation, the rate-limiting step in translation. To inde-
pendently test whether a bulk increase in protein synthesis un-
derlies G2019S LRRK2 toxicity, flies were treated with the global
protein synthesis inhibitor anisomycin. Chronic low-dose aniso-
mycin treatment throughout adulthood rescued locomotor defi-
cits and dopamine neuron loss in aged G2019S LRRK2 trans-
genic Drosophila, whereas no effects of the drug were seen in
control flies (Figures 7D and 7E). Anisomycin treatment did not
affect LRRK2 expression levels (Figure S7E) or s15 phosphoryla-
tion (Figure S7F) but did reduce the increase in translation
observed in G2019S LRRK2 transgenic flies (Figure S7G). The
rescue effect of anisomycin supports our conclusion that
elevated bulk protein synthesis underlies G2019S LRRK2
toxicity.
DISCUSSION
Themajor finding from this study is the identification, via a screen
for LRRK2 kinase substrates, of s15 as a novel in vivo LRRK2
substrate that underlies PD-related phenotypes in Drosophila
and directly links LRRK2 toxicity to altered mRNA translation.
Screening for LRRK2-interacting proteins revealed numerousCell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc. 479
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ribosomal proteins and led to the discovery that LRRK2 is en-
riched in the ribosomal subcellular fraction. Further screening
of all ribosomal proteins as candidate LRRK2 substrates re-
vealed that s15 is a strong LRRK2 substrate, which although
not identified in the original screen, interacts directly with
LRRK2 in coimmunoprecipitation studies. In vitro phosphoryla-
tion assays indicate that wild-type LRRK2 phosphorylates a
number of ribosomal proteins, of which s15 phosphorylation
transduces LRRK2-related toxicity and regulation of cap-
dependent and cap-independent translation. s15 fulfills several
criteria as a substrate for LRRK2 including enhanced phosphor-
ylation in LRRK2 transgenic Drosophila brain and human brain
expressing the common G2019S mutation and in HEK293 cells
expressing G2019S LRRK2, where it is blocked by two specific
and unrelated LRRK2 kinase inhibitors. Moreover, s15 phos-
phorylation is significantly reduced in flies null for the Drosophila
LRRK2 homolog, dLRRK. s15 phosphorylation is central to
G2019S LRRK2 toxicity because T136A s15 blocks G2019S
LRRK2 toxicity in human dopamine neurons and additionally
blocks neurodegeneration, locomotor deficits, and elevated
protein synthesis observed in a Drosophila in vivo PD model.
While wild-type s15 coexpression appears to provide a minor
protective effect in rat cortical neuron cultures overexpressing
G2019S LRRK2 (Figure 2B), it was not protective in other
neuronal culture experiments or in G2019S LRRK2 transgenic
flies, in contrast to T136A s15 coexpression, which produces a
clear and significant protective effect in all neuronal culture ex-
periments and Drosophila neurodegenerative phenotypes
examined. It is possible that the small protective effect seen in
rat cortical neurons may be related to a minor competitive effect
of extra cytosolic s15 that might reduce phosphorylation of s15
by LRRK2 directly at the ribosome in this context. Informatively,
wild-type LRRK2 overexpression in Drosophila causes a slight
increase in s15 phosphorylation and, as observed in previous
studies (Liu et al., 2008), leads to a modest effect on locomotion
and dopamine neuron viability, which are more pronounced with
G2019S LRRK2 expression. This supports a well-established
link between LRRK2 kinase activity and neurotoxicity and sug-
gests that wild-type LRRK2 overexpression could in theory result
in pathology if expressed at high enough levels. Consistent with
this, elevated wild-type LRRK2 overexpression in neuronal
cultures results in slightly increased s15 phosphorylation and
neuronal toxicity, but not to the extent observed with G2019S
LRRK2 expression, suggesting, as previously reported, that
additional mechanisms may differentially regulate the kinase
activities of wild-type and mutant forms of LRRK2 in vivo, effec-Figure 6. G2019S LRRK2 Stimulates Cap-Dependent and Cap-Indepen
(A) Bicistronic reporter assay for assessing effects of LRRK2 on cap-dependent
(B) G2019S LRRK2 stimulates cap-dependent (FLAG-GFP) and cap-indepen
(SH-SY5Y) cells (individual two-way ANOVA, effect of LRRK2 dose, p % 0.00
G2019S/D1994A (GS/DA) (Bonferroni posttests, *p < 0.05, **p < 0.01, ***p < 0.00
(C) V5 s15 stimulates cap-dependent and cap-independent reporter translation
two-way ANOVA, effect of s15 variant, p% 0.0073, effect of dose, p% 0.0099,
(D) G2019S LRRK2-stimulated cap-dependent (c.d.) and cap-independent (c
p% 0.0014, Bonferroni posttest, *p < 0.05, **p < 0.01, n = 8) while bicistronic re
(E) In human cortical neurons, G2019S LRRK2-stimulated reporter expression,
ANOVA, Bonferroni posttest, *p < 0.05, ***p < 0.001, n = 4). Scale bars represen
See also Figure S6.tively dampening the kinase activity of wild-type LRRK2 (Sen
et al., 2009; Webber et al., 2011). While we observe an increase
in P-s15 and rescue effect of T136A s15 for the kinase domain
mutants G2019S and I2020T LRRK2, R1441C LRRK2 does not
show similar phenotypes, suggesting that alternative pathogenic
mechanisms leading to PD may result from this mutation,
possibly involving other pathogenic substrates or perhaps
even kinase-independent pathways. Future detailed studies
are necessary to understand the consequences of ROC domain
mutations on LRRK2 function and neurotoxicity.
Studies in Drosophila models of LRRK2 toxicity suggest that
LRRK2 mutants with increased kinase activity can stimulate 4E-
BP1 phosphorylation and expression of transcription factors
e2f1 and dp through unclear mechanisms possibly involving
elevated levels of free eIF4E or perturbed miRNA function
(Gehrke et al., 2010; Imai et al., 2008; Tain et al., 2009). Evi-
dence showing that 4E-BP is a direct LRRK2 substrate or that
4E-BP has a role in miRNA function is lacking, however, and
importantly there has been no demonstration that LRRK2-medi-
ated phosphorylation of 4E-BP directly mediates altered trans-
lation of the few mRNAs mentioned. Subsequent studies have
failed to detect an increase in P-4E-BP in cells or mouse brain
following increased LRRK2 kinase activity (Kumar et al., 2010;
Trancikova et al., 2012). Our data from in vitro reporter assays
and Drosophila suggest that G2019S LRRK2 actually promotes
an increase in bulk translation and provide a mechanism by
which G2019S LRRK2 directly stimulates cap-dependent and
cap-independent translation at the ribosomal level through
phosphorylation of s15. Our results also indicate that patho-
genic LRRK2 does not cause a systematic effect on either
mode of translation via 4E-BP phosphorylation or disruption
of the miRNA pathway. Thus, the observation that overexpres-
sion of 4E-BP or reduction in dLRRK levels can be protective in
Drosophila models of PINK1 and Parkin pathology may be
accounted for by a potential for modulated 4E-BP expression
to dampen aberrant protein production as opposed to direct
interference with LRRK2 substrate phosphorylation-mediated
signaling (Tain et al., 2009). Consistent with this notion are our
observations that the global protein synthesis inhibitor aniso-
mycin rescues the locomotor deficits and dopamine neuron
loss in aged G2019S LRRK2 transgenic Drosophila. Further
studies investigating a possible role of altered translation
following other genetic mutations linked to PD are warranted
by this finding.
Defects in translational regulation underlie a number of
inherited diseases. These diseases exhibit a high degree ofdent Translation
and cap-independent translation.
dent (c-Myc-GFP) bicistronic reporter translation in human neuroblastoma
75, and genotype, p < 0.002, n = 3), in a kinase-dependent manner versus
1, ****p < 0.0001, n = 3).
which is reduced by T136A and potentiated by T136D mutations (individual
n = 3).
.i.) reporter translation is attenuated by V5-T136A s15 (individual ANOVA,
porter mRNA was not significantly different (ANOVA, ns, n = 8).
toxicity, and cell death are rescued by T136A s15 coexpression (individual
t 25 mM. Data are mean ± SEM.
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Figure 7. Elevated Protein Synthesis in G2019S LRRK2 Transgenic Flies Is Blocked by T136A s15
(A) De novo protein synthesis, measured by 35S-met/cys incorporation is significantly increased in protein precipitates fromG2019S LRRK2 transgenic fly heads,
which is blocked by T136A s15 coexpression (*p < 0.05, n = 5 groups of 50 heads/genotype). Genotypes areDa-Gal4 alone (Control),Da-Gal4; UAS-LRRK2 (WT),
Da-Gal4/UAS-G2019S/D1994A LRRK2 (GS/DA), Da-Gal4; UAS-G2019S LRRK2 (G2019S), Da-Gal4/UAS-T136A s15; UAS-G2019S LRRK2 (GS+TA s15).
(B) Autoradiography from lysates reveals a widespread increase in 35S-met/cys-labeled protein abundance. Ponceau staining for total protein.
(C) Fractions collected from fly head polysome profiles and used for RT-PCR of translating mRNA indicates a G2019S LRRK2-mediated shift in tubulin and actin
5C to heavy polysome fractions, prevented by T136A s15 (two-way ANOVA, Bonferroni posttest, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3 groups of 100 fly heads/
genotype).
(D) Confocal z stack projection images and quantitation of dopamine neurons in Drosophila brains. Anisomycin (10 mM) treatment to food throughout adulthood
rescued dopamine neuron loss in aged G2019S transgenic flies (individual ANOVA, Bonferroni posttest, *p < 0.05, **p < 0.01, n = 8–10 fly heads per genotype).
(E) Anisomycin treatment prevented age-related locomotor deficits in G2019S flies (ANOVA, Bonferroni posttest, *p < 0.05, **p < 0.01, n = 25 flies per genotype).
Genotypes for (D) and (E) are as in (A). Data are mean ± SEM.
See also Figure S7.heterogeneity despite the fact that protein synthesis is a funda-
mental process of all cells (Scheper et al., 2007). In the nervous
system, excessive protein synthesis has long been implicated in
the development of Fragile X syndrome (reviewed in [Bhakar
et al., 2012]). More recently, systematically altered translation482 Cell 157, 472–485, April 10, 2014 ª2014 Elsevier Inc.has been identified as a fundamental mechanism driving prion
disease neurodegeneration (Moreno et al., 2012) and perturbed
RNA metabolism through mutations in RNA binding proteins
such as TAR DNA binding protein-43 (TDP-43) and fused in
sarcoma/translocated in sarcoma (FUS/TLS) has been
implicated in the pathogenesis of amyotrophic lateral sclerosis
and frontotemporal dementia (Lagier-Tourenne et al., 2012;
Polymenidou et al., 2011; Tollervey et al., 2011). Thus,
loss of translational control is emerging as an important
mediator of diverse neurologic diseases. A molecular under-
standing of how aberrant protein synthesis leads to neurodegen-
eration in these diseases will be an important future priority.
In summary, these findings support a role for dysregulated
translation in the pathogenesis of PD. Consistent with this notion
is the recent observation that mutations in the translation initia-
tion factor eIF4G1 cause autosomal dominant PD (Chartier-
Harlin et al., 2011; Nuytemans et al., 2013). Whether mutations
in LRRK2 and eIF4G1 converge on common or overlapping path-
ogenic outputs are under detailed investigation. As mentioned
above, elevated or impaired translation has been identified as
a causative factor in numerous neurological diseases and
emphasizes the importance of protein homeostasis in neuronal
function. Thus, further understanding the role of translation in
the degenerative process of PD will provide new targets for
disease modification in PD.
EXPERIMENTAL PROCEDURES
LRRK2 Tandem Affinity Purification
LRRK2-interacting phosphoproteins were identified using tandem affinity
purification of TAP tagged LRRK2 from HEK293 cells, IMAC phosphoprotein
enrichment and mass spectrometry in series. Full description of the method
is provided in the Supplemental Information.
LRRK2 In Vitro Kinase Assays
Recombinant LRRK2 (aa 970–2,527) and recombinant GST-tagged substrate
candidates were incubated in kinase assay buffer containing g-P32-ATP for
phosphorimaging-based visualization of protein phosphorylation following
separation of the reaction mixture by SDS-PAGE. See Supplemental
Information for full details.
LRRK2 In Vitro Toxicity Assays
Toxicity (loss of neurites and appearance of TUNEL-positive nuclei) in rodent
and human neurons overexpressing LRRK2, substrate and GFP for neurite
tracing in a 10:10:1 ratio was assessed using previously described methods
48 hr following plasmid transfection (Lee et al., 2010; Li et al., 2010; Ramsden
et al., 2011; Xiong et al., 2010). The vast majority of GFP positive neurons
(90%) also colabeled for overexpressed LRRK2 and substrate indicating
that the effects of LRRK2 and s15/s11 overexpression could be assessed in
these neurons, as previously described (Lee et al., 2010). See Supplemental
Information for more details. Research involving human pluripotent stem cells
(hPSCs) was subject to oversight and approval by the Johns Hopkins Univer-
sity Institutional Stem Cell Research Oversight (ISCRO) Committee. Research
involving animal subjects was subject to oversight and approval by the Johns
Hopkins University Animal Care and Use Program.
Generation of s15 and T136A s15 Transgenic Lines
Human s15 and T136A s15 constructs were generated by subcloning
full-length cDNA into pUAST between EcoR1 and Xba1 restriction sites. After
sequence verification, constructs were microinjected into w1118 fly embryos.
Transgenic UAS-s15 and UAS-T136A s15 expression were confirmed by
western blot on fly heads following expression driven via daughterless-Gal4
(Figure S5A). Details on additional fly lines used are provided in Supplemental
Information.
Phospho-s15 Assessment in Cells and Drosophila
A polyclonal antibody to phospho-Thr136 was generated and validated as
described in the Supplemental Information. In cells, phosphorylation ofoverexpressed s15 was assessed from whole lysates extracted using 1%
NP-40 lysis buffer and separated by SDS-PAGE for immunoblotting. In
homogenized heads of LRRK2 transgenic or dLRRK null flies, phosphoryla-
tion of endogenous s15was assessed in ribosomal fractions that were isolated
essentially as described before (Belin et al., 2010) with the addition of
phosphatase inhibitors to the extraction buffer.
Drosophila Dopamine Neuron Immunohistochemistry
and Locomotor Function
Dopamine neuron immunohistochemistry and negative geotaxis assess-
ment of locomotor function were performed as described in Supplemental
Information.
De Novo Protein Synthesis and mRNA Polysome Profiling in
Drosophila
For protein synthesis measurement, 35S-methionine/cysteine (100 mCi/ml)
incorporation into flies fed with labeled food for 24 hr was assessed by liquid
scintillation counting and expressed relative to total protein amount.
Polysomes were isolated from fly heads via sucrose gradient centrifugation
and fractionated for RNA extraction, cDNA synthesis and real-time PCR
measurement of genes relative to a spike-in luciferase synthetic RNA added
prior to RNA extraction as previously described (Thoreen et al., 2012). See
Supplemental Information for full details.
Statistical Analyses
All statistical analyses, including Student’s t tests, ANOVA, and associated
Bonferroni posttests were performed using GraphPad Prism software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2014.01.064.
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